Skip to main content
Erschienen in: International Urology and Nephrology 2/2017

01.11.2016 | Nephrology – Review

A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument

verfasst von: Nigar Sekercioglu, Reem Al-Khalifah, Joycelyne Efua Ewusie, Rosilene M. Elias, Lehana Thabane, Jason W. Busse, Noori Akhtar-Danesh, Alfonso Iorio, Tetsuya Isayama, Juan Pablo Díaz Martínez, Ivan D. Florez, Gordon H. Guyatt

Erschienen in: International Urology and Nephrology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with chronic kidney disease mineral and bone disorders (CKD-MBD) suffer high rates of morbidity and mortality, in particular related to bone and cardiovascular outcomes. The management of CKD-MBD remains challenging. The objective of this systematic survey is to critically appraise clinical practice guidelines (CPGs) addressing CKD-MBD.

Methods/design

Data sources included MEDLINE, EMBASE, the National Guideline Clearinghouse, Guideline International Network and Turning Research into Practice up to May 2016. Teams of two reviewers, independently and in duplicate, screened titles and abstracts and potentially eligible full text reports to determine eligibility and subsequently appraised the guidelines using the Advancing Guideline Development, Reporting and Evaluation in Health Care instrument II (AGREE).

Results

Sixteen CPGs published from 2003 to 2015 addressing the diagnosis and management of CKD-MBD in adult patients (11 English, two Spanish, one Italian, one Portuguese and one Slovak) proved eligible. The National Institute for Health and Care Excellence guideline performed best with respect to AGREE II criteria; only three other CPGs warranted high scores on all domains. All other guidelines received scores of under 60% on one or more domains. Major discrepancies in recommendations were not, however, present, and we found no association between quality of CPGs which was not associated with resulting recommendations.

Conclusions

Most guidelines assessing CKD-MBD suffer from serious shortcomings using AGREE criteria although limitations with respect to AGREE criteria do not necessarily lead to inappropriate recommendations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382(9888):260–272CrossRefPubMed Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382(9888):260–272CrossRefPubMed
2.
Zurück zum Zitat National Institutes of Health NIoDaDaKD (2015) United States renal data system. 2015 USRDS annual data report: epidemiology of kidney disease in the United States. United States Renal Data System, Bathesda National Institutes of Health NIoDaDaKD (2015) United States renal data system. 2015 USRDS annual data report: epidemiology of kidney disease in the United States. United States Renal Data System, Bathesda
3.
Zurück zum Zitat Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB (2004) Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol: JASN 15(5):1300–1306CrossRefPubMed Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB (2004) Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol: JASN 15(5):1300–1306CrossRefPubMed
4.
Zurück zum Zitat Levey AS, Atkins R, Coresh J et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from kidney disease improving global outcomes. Kidney Int 72(3):247–259CrossRefPubMed Levey AS, Atkins R, Coresh J et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from kidney disease improving global outcomes. Kidney Int 72(3):247–259CrossRefPubMed
5.
Zurück zum Zitat Cortes-Sanabria L, Rodriguez-Arreola BE, Ortiz-Juarez VR et al (2013) Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis. Perit Dial Int: J Int Soc Perit Dial 33(6):679–686CrossRef Cortes-Sanabria L, Rodriguez-Arreola BE, Ortiz-Juarez VR et al (2013) Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis. Perit Dial Int: J Int Soc Perit Dial 33(6):679–686CrossRef
6.
Zurück zum Zitat Suja A, Anju R, Anju V, Neethu J, Peeyush P, Saraswathy R (2012) Economic evaluation of end stage renal disease patients undergoing hemodialysis. J Pharm Bioallied Sci 4(2):107–111CrossRefPubMedPubMedCentral Suja A, Anju R, Anju V, Neethu J, Peeyush P, Saraswathy R (2012) Economic evaluation of end stage renal disease patients undergoing hemodialysis. J Pharm Bioallied Sci 4(2):107–111CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Laliberte F, Bookhart BK, Vekeman F et al (2009) Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm: JMCP 15(4):312–322PubMed Laliberte F, Bookhart BK, Vekeman F et al (2009) Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm: JMCP 15(4):312–322PubMed
8.
Zurück zum Zitat Group KDIGOKCW: KDIGO (2012) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013(3):1–150 Group KDIGOKCW: KDIGO (2012) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013(3):1–150
9.
Zurück zum Zitat Moe SM (2006) Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36:51–62CrossRefPubMed Moe SM (2006) Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36:51–62CrossRefPubMed
10.
Zurück zum Zitat Sanchez-Perales C, Vazquez Ruiz de Castroviejo E, Garcia-Cortes MJ, Biechy Mdel M, Gil-Cunquero JM, Borrego-Hinojosa J et al (2015) Valvular calcifications at the start of dialysis predict the onset of cardiovascular events in the course of follow-up. Nefrologia 35(2):157–163. doi:10.1016/j.nefro.2015.05.017 CrossRefPubMed Sanchez-Perales C, Vazquez Ruiz de Castroviejo E, Garcia-Cortes MJ, Biechy Mdel M, Gil-Cunquero JM, Borrego-Hinojosa J et al (2015) Valvular calcifications at the start of dialysis predict the onset of cardiovascular events in the course of follow-up. Nefrologia 35(2):157–163. doi:10.​1016/​j.​nefro.​2015.​05.​017 CrossRefPubMed
11.
Zurück zum Zitat Rebic D, Rasic C (2015) Valvular calcification and left ventricular modifying in peritoneal dialysis patients. Renal Fail 19:1–7 Rebic D, Rasic C (2015) Valvular calcification and left ventricular modifying in peritoneal dialysis patients. Renal Fail 19:1–7
13.
Zurück zum Zitat Arenas MD, Alvarez-Ude F, Gil MT et al (2007) Implementation of ‘K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease’ after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transpl 22(6):1639–1644CrossRef Arenas MD, Alvarez-Ude F, Gil MT et al (2007) Implementation of ‘K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease’ after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transpl 22(6):1639–1644CrossRef
14.
Zurück zum Zitat Wetmore JB, Quarles LD (2009) Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 5(1):24–33CrossRefPubMed Wetmore JB, Quarles LD (2009) Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 5(1):24–33CrossRefPubMed
15.
Zurück zum Zitat Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6(4):913–921CrossRefPubMed Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6(4):913–921CrossRefPubMed
16.
Zurück zum Zitat Pitt SC, Sippel RS, Chen H (2009) Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin N Am 89(5):1227–1239CrossRefPubMedPubMedCentral Pitt SC, Sippel RS, Chen H (2009) Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin N Am 89(5):1227–1239CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Cernaro V, Santoro D, Lacquaniti A et al (2016) Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis 9:11–19CrossRefPubMedPubMedCentral Cernaro V, Santoro D, Lacquaniti A et al (2016) Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis 9:11–19CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Jamal et al (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382(9900):1268–1277. doi:10.1016/S0140-6736(13)60897 CrossRefPubMed Jamal et al (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382(9900):1268–1277. doi:10.​1016/​S0140-6736(13)60897 CrossRefPubMed
19.
Zurück zum Zitat Zhai CJ et al (2015) Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 47(3):527–535. doi:10.1007/s11255-014-0876-x CrossRefPubMed Zhai CJ et al (2015) Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 47(3):527–535. doi:10.​1007/​s11255-014-0876-x CrossRefPubMed
20.
Zurück zum Zitat Patel L, Bernard M (2015) Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 14:06800615 Patel L, Bernard M (2015) Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 14:06800615
21.
Zurück zum Zitat Meyer C, Cameron K, Battistella M (2012) New agent to treat elevated phosphate levels: magnesium carbonate/calcium carbonate tablets. CANNT J J ACITN 22(4):33–35 quiz 36-37 Meyer C, Cameron K, Battistella M (2012) New agent to treat elevated phosphate levels: magnesium carbonate/calcium carbonate tablets. CANNT J J ACITN 22(4):33–35 quiz 36-37
22.
Zurück zum Zitat Field B, Booth A, Ilott I, Gerrish K (2014) Using the knowledge to action framework in practice: a citation analysis and systematic review. Implement Sci: IS 9:172CrossRefPubMedPubMedCentral Field B, Booth A, Ilott I, Gerrish K (2014) Using the knowledge to action framework in practice: a citation analysis and systematic review. Implement Sci: IS 9:172CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D (2005) A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. Int J Qual Health Care 17(3):235–242. doi:10.1093/intqhc/mzi027 CrossRefPubMed Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D (2005) A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. Int J Qual Health Care 17(3):235–242. doi:10.​1093/​intqhc/​mzi027 CrossRefPubMed
25.
Zurück zum Zitat Cluzeau FA, Littlejohns P, Grimshaw JM, Feder G, Moran SE (1999) Development and application of a generic methodology to asess the quality of clinical guidelines. Int J Qual Health Care 11:21–28CrossRefPubMed Cluzeau FA, Littlejohns P, Grimshaw JM, Feder G, Moran SE (1999) Development and application of a generic methodology to asess the quality of clinical guidelines. Int J Qual Health Care 11:21–28CrossRefPubMed
26.
Zurück zum Zitat Yan J, Min J, Zhou B (2013) Diagnosis of pheochromocytoma: a clinical practice guideline appraisal using AGREE II instrument. J Eval Clin Pract 19(4):626–632CrossRefPubMed Yan J, Min J, Zhou B (2013) Diagnosis of pheochromocytoma: a clinical practice guideline appraisal using AGREE II instrument. J Eval Clin Pract 19(4):626–632CrossRefPubMed
27.
Zurück zum Zitat Barriocanal AM, Lopez A, Monreal M, Montane E (2016) Quality assessment of peripheral artery disease clinical guidelines. J Vasc Surg 63(4):1091–1098CrossRefPubMed Barriocanal AM, Lopez A, Monreal M, Montane E (2016) Quality assessment of peripheral artery disease clinical guidelines. J Vasc Surg 63(4):1091–1098CrossRefPubMed
28.
Zurück zum Zitat Manns BJ, Hodsman A, Zimmerman DL et al (2010) Canadian society of nephrology commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 55(5):800–812CrossRefPubMed Manns BJ, Hodsman A, Zimmerman DL et al (2010) Canadian society of nephrology commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 55(5):800–812CrossRefPubMed
29.
Zurück zum Zitat National Kideny Foudation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1–201 National Kideny Foudation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1–201
30.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. doi:10.1038/ki.2009.188 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. doi:10.​1038/​ki.​2009.​188
31.
Zurück zum Zitat Centre for Clinical Practice at N (2013) National Institute for Health and Clinical Excellence: Guidance. Hyperphosphataemia in chronic kidney disease: management of hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease. National Institute for Health and Clinical Excellence (UK)Copyright (c) National Institute for Health and Clinical Excellence, Manchester Centre for Clinical Practice at N (2013) National Institute for Health and Clinical Excellence: Guidance. Hyperphosphataemia in chronic kidney disease: management of hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease. National Institute for Health and Clinical Excellence (UK)Copyright (c) National Institute for Health and Clinical Excellence, Manchester
32.
Zurück zum Zitat (2014) Hyperphosphataemia in chronic kidney disease evidence update December 2014. NICE guidelines (2014) Hyperphosphataemia in chronic kidney disease evidence update December 2014. NICE guidelines
33.
Zurück zum Zitat Chadban S, Chan M, Fry K et al (2010) The CARI guidelines. Nutritional interventions for the prevention of bone disease in kidney transplant recipients. Nephrology (Carlton, Vic) 15(Suppl 1):S43–S47CrossRef Chadban S, Chan M, Fry K et al (2010) The CARI guidelines. Nutritional interventions for the prevention of bone disease in kidney transplant recipients. Nephrology (Carlton, Vic) 15(Suppl 1):S43–S47CrossRef
34.
Zurück zum Zitat Elder G, Faull R, Branley P, Hawley C (2006) The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton, Vic) 11(Suppl 1):S230–S261CrossRef Elder G, Faull R, Branley P, Hawley C (2006) The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton, Vic) 11(Suppl 1):S230–S261CrossRef
35.
Zurück zum Zitat Hawley C, Elder G (2006) The CARI guidelines. Biochemical targets. Nephrology (Carlton, Vic) 11(Suppl 1):S198–S216 Hawley C, Elder G (2006) The CARI guidelines. Biochemical targets. Nephrology (Carlton, Vic) 11(Suppl 1):S198–S216
38.
Zurück zum Zitat Fukagawa M, Yokoyama K, Koiwa F et al (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apheresis Dial 17(3):247–288CrossRef Fukagawa M, Yokoyama K, Koiwa F et al (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apheresis Dial 17(3):247–288CrossRef
39.
Zurück zum Zitat Jindal K, Chan CT, Deziel C et al (2006) Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol: JASN 17(3 Suppl 1):S1–27PubMed Jindal K, Chan CT, Deziel C et al (2006) Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol: JASN 17(3 Suppl 1):S1–27PubMed
40.
Zurück zum Zitat Levin A, Hemmelgarn B, Culleton B et al (2008) Guidelines for the management of chronic kidney disease. CMAJ. Can Med Assoc J 179(11):1154–1162CrossRef Levin A, Hemmelgarn B, Culleton B et al (2008) Guidelines for the management of chronic kidney disease. CMAJ. Can Med Assoc J 179(11):1154–1162CrossRef
41.
Zurück zum Zitat Torregrosa JV, Cannata Andia J, Bover J et al (2008) SEN guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients. Nefrologia 28(Suppl 1):1–22PubMed Torregrosa JV, Cannata Andia J, Bover J et al (2008) SEN guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients. Nefrologia 28(Suppl 1):1–22PubMed
42.
Zurück zum Zitat Prados-Garrido MD, Bover J, Teresa González-Álvarez M (2011) Clinical practice guideline for chronic kidney disease-mineral and bone disease (2010 version). Dialisis Transplante 32(3):108–118 Prados-Garrido MD, Bover J, Teresa González-Álvarez M (2011) Clinical practice guideline for chronic kidney disease-mineral and bone disease (2010 version). Dialisis Transplante 32(3):108–118
43.
Zurück zum Zitat Mazzaferro S, Cozzolino M, Marangella M, Strippoli GF, Messa P (2007) Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology. Giornale italiano di nefrologia 24(Suppl 37):S107–S124PubMed Mazzaferro S, Cozzolino M, Marangella M, Strippoli GF, Messa P (2007) Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology. Giornale italiano di nefrologia 24(Suppl 37):S107–S124PubMed
44.
Zurück zum Zitat Carvalho AB, Gueiros AP, Gueiros JE et al (2012) Guidelines on bone mineral disorder in chronic kidney disease–addendum chapter 2. Jornal brasileiro de nefrologia 34(2):199–205CrossRefPubMed Carvalho AB, Gueiros AP, Gueiros JE et al (2012) Guidelines on bone mineral disorder in chronic kidney disease–addendum chapter 2. Jornal brasileiro de nefrologia 34(2):199–205CrossRefPubMed
45.
Zurück zum Zitat Anonymous (2009) Guidelines of the Ministry of Health of the Slovak Republic for the treatment of bone and mineral metabolism disorders in patients with chronic kidney disease. Aktuality v Nefrologii 15(3):121–127 Anonymous (2009) Guidelines of the Ministry of Health of the Slovak Republic for the treatment of bone and mineral metabolism disorders in patients with chronic kidney disease. Aktuality v Nefrologii 15(3):121–127
46.
Zurück zum Zitat Guyatt GH, Oxman AD, Santesso N et al (2013) GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 66(2):158–172CrossRefPubMed Guyatt GH, Oxman AD, Santesso N et al (2013) GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 66(2):158–172CrossRefPubMed
47.
Zurück zum Zitat Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.) 336(7650):924–926CrossRef Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.) 336(7650):924–926CrossRef
48.
Zurück zum Zitat Zarnke KB, Campbell NR, McAlister FA, Levine M (2000) A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol 16(9):1094–1102PubMed Zarnke KB, Campbell NR, McAlister FA, Levine M (2000) A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol 16(9):1094–1102PubMed
49.
Zurück zum Zitat Djulbegovic B, Guyatt GH (2014) Evidence-based practice is not synonymous with delivery of uniform health care. JAMA 312(13):1293–1294CrossRefPubMed Djulbegovic B, Guyatt GH (2014) Evidence-based practice is not synonymous with delivery of uniform health care. JAMA 312(13):1293–1294CrossRefPubMed
50.
Zurück zum Zitat Smith CA, Toupin-April K, Jutai JW et al (2015) A systematic critical appraisal of clinical practice guidelines in juvenile idiopathic arthritis using the appraisal of guidelines for research and evaluation II (AGREE II) instrument. PLoS One 10(9):e0137180CrossRefPubMedPubMedCentral Smith CA, Toupin-April K, Jutai JW et al (2015) A systematic critical appraisal of clinical practice guidelines in juvenile idiopathic arthritis using the appraisal of guidelines for research and evaluation II (AGREE II) instrument. PLoS One 10(9):e0137180CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Brosseau L, Rahman P, Poitras S et al (2014) A systematic critical appraisal of non-pharmacological management of rheumatoid arthritis with appraisal of guidelines for research and evaluation II. PLoS One 9(5):e95369CrossRefPubMedPubMedCentral Brosseau L, Rahman P, Poitras S et al (2014) A systematic critical appraisal of non-pharmacological management of rheumatoid arthritis with appraisal of guidelines for research and evaluation II. PLoS One 9(5):e95369CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Brosseau L, Rahman P, Toupin-April K et al (2014) A systematic critical appraisal for non-pharmacological management of osteoarthritis using the appraisal of guidelines research and evaluation II instrument. PLoS One 9(1):e82986CrossRefPubMedPubMedCentral Brosseau L, Rahman P, Toupin-April K et al (2014) A systematic critical appraisal for non-pharmacological management of osteoarthritis using the appraisal of guidelines research and evaluation II instrument. PLoS One 9(1):e82986CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Hazlewood GS, Akhavan P, Schieir O et al (2014) Adding a “GRADE” to the quality appraisal of rheumatoid arthritis guidelines identifies limitations beyond AGREE-II. J Clin Epidemiol 67(11):1274–1285CrossRefPubMed Hazlewood GS, Akhavan P, Schieir O et al (2014) Adding a “GRADE” to the quality appraisal of rheumatoid arthritis guidelines identifies limitations beyond AGREE-II. J Clin Epidemiol 67(11):1274–1285CrossRefPubMed
54.
Zurück zum Zitat Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D (2005) A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. Int J Qual Health Care 17(3):235–242CrossRefPubMed Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D (2005) A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. Int J Qual Health Care 17(3):235–242CrossRefPubMed
55.
Zurück zum Zitat Watine J, Friedberg B, Nagy E et al (2006) Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. Clin Chem 52(1):65–72CrossRefPubMed Watine J, Friedberg B, Nagy E et al (2006) Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. Clin Chem 52(1):65–72CrossRefPubMed
Metadaten
Titel
A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument
verfasst von
Nigar Sekercioglu
Reem Al-Khalifah
Joycelyne Efua Ewusie
Rosilene M. Elias
Lehana Thabane
Jason W. Busse
Noori Akhtar-Danesh
Alfonso Iorio
Tetsuya Isayama
Juan Pablo Díaz Martínez
Ivan D. Florez
Gordon H. Guyatt
Publikationsdatum
01.11.2016
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 2/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-016-1436-3

Weitere Artikel der Ausgabe 2/2017

International Urology and Nephrology 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.